ZEAL - （Zealand Pharma A/S）ZEALのニュース
Zealand Pharma’s (NASDAQ:ZEAL) Phase 3 SBS Trial Sees Positive Results 2022/09/30 11:41:11 TipRanks
Biotechnology company Zealand Pharma (NASDAQ:ZEAL) has delivered positive topline results from the Phase 3 trial of glepaglutide for the treatment of short bowel syndrome (SBS). The trial met its primary endpoint and the twice-weekly dosing regimen showed a statistically significant decrease in weekly parental support at 24 weeks. The treatment was deemed safe and was well tolerated.
ZEAL stock on watch as short bowel syndrome therapy hits main goal in trial (NASDAQ:ZEAL) 2022/09/30 10:51:55 Seeking Alpha
Danish biotech Zealand Pharma A/S (ZEAL) announced Friday that the company’s Phase 3 trial for glepaglutide, an experimental therapy designed for subcutaneous delivery via an…
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels 2022/09/07 11:00:47 Benzinga
Zealand Pharma A/S (NASDAQ: ZEAL ) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE: NVO ) to commercialize Zegalogue (dasiglucagon) for injection. FDA approved Zegalogue for severe hypoglycemia in pediatric and adult patients with diabetes aged six and above. Under the terms of the agreement, Zealand will receive an … Full story available on Benzinga.com
Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q2 2022 Results - Earnings Call Transcript 2022/08/11 17:16:22 Seeking Alpha
Zealand Pharma A/S (ZEAL) Q2 2022 Earnings Conference Call August 11, 2022, 10:00 AM ET Company Participants Anna Krassowska - VP of IR and Corporate Communications Adam Steensberg -…
Why Zealand Pharma Shares Are Rising 2022/05/19 14:34:53 Benzinga
Zealand Pharma A/S - ADR (NASDAQ: ZEAL ) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital hyperinsulinism met the primary endpoint with statistical significance. Based on the trial''s … Full story available on Benzinga.com
Zealand Pharma’s (NASDAQ:ZEAL) Phase 3 SBS Trial Sees Positive Results 2022/09/30 11:41:11 TipRanks
Biotechnology company Zealand Pharma (NASDAQ:ZEAL) has delivered positive topline results from the Phase 3 trial of glepaglutide for the treatment of short bowel syndrome (SBS). The trial met its primary endpoint and the twice-weekly dosing regimen showed a statistically significant decrease in weekly parental support at 24 weeks. The treatment was deemed safe and was well tolerated.
ZEAL stock on watch as short bowel syndrome therapy hits main goal in trial (NASDAQ:ZEAL) 2022/09/30 10:51:55 Seeking Alpha
Danish biotech Zealand Pharma A/S (ZEAL) announced Friday that the company’s Phase 3 trial for glepaglutide, an experimental therapy designed for subcutaneous delivery via an…
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels 2022/09/07 11:00:47 Benzinga
Zealand Pharma A/S (NASDAQ: ZEAL ) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE: NVO ) to commercialize Zegalogue (dasiglucagon) for injection. FDA approved Zegalogue for severe hypoglycemia in pediatric and adult patients with diabetes aged six and above. Under the terms of the agreement, Zealand will receive an … Full story available on Benzinga.com
Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q2 2022 Results - Earnings Call Transcript 2022/08/11 17:16:22 Seeking Alpha
Zealand Pharma A/S (ZEAL) Q2 2022 Earnings Conference Call August 11, 2022, 10:00 AM ET Company Participants Anna Krassowska - VP of IR and Corporate Communications Adam Steensberg -…
Why Zealand Pharma Shares Are Rising 2022/05/19 14:34:53 Benzinga
Zealand Pharma A/S - ADR (NASDAQ: ZEAL ) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital hyperinsulinism met the primary endpoint with statistical significance. Based on the trial''s … Full story available on Benzinga.com
Zealand Pharma’s (NASDAQ:ZEAL) Phase 3 SBS Trial Sees Positive Results 2022/09/30 11:41:11 TipRanks
Biotechnology company Zealand Pharma (NASDAQ:ZEAL) has delivered positive topline results from the Phase 3 trial of glepaglutide for the treatment of short bowel syndrome (SBS). The trial met its primary endpoint and the twice-weekly dosing regimen showed a statistically significant decrease in weekly parental support at 24 weeks. The treatment was deemed safe and was well tolerated.
ZEAL stock on watch as short bowel syndrome therapy hits main goal in trial (NASDAQ:ZEAL) 2022/09/30 10:51:55 Seeking Alpha
Danish biotech Zealand Pharma A/S (ZEAL) announced Friday that the company’s Phase 3 trial for glepaglutide, an experimental therapy designed for subcutaneous delivery via an…
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels 2022/09/07 11:00:47 Benzinga
Zealand Pharma A/S (NASDAQ: ZEAL ) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE: NVO ) to commercialize Zegalogue (dasiglucagon) for injection. FDA approved Zegalogue for severe hypoglycemia in pediatric and adult patients with diabetes aged six and above. Under the terms of the agreement, Zealand will receive an … Full story available on Benzinga.com
Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q2 2022 Results - Earnings Call Transcript 2022/08/11 17:16:22 Seeking Alpha
Zealand Pharma A/S (ZEAL) Q2 2022 Earnings Conference Call August 11, 2022, 10:00 AM ET Company Participants Anna Krassowska - VP of IR and Corporate Communications Adam Steensberg -…
Why Zealand Pharma Shares Are Rising 2022/05/19 14:34:53 Benzinga
Zealand Pharma A/S - ADR (NASDAQ: ZEAL ) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital hyperinsulinism met the primary endpoint with statistical significance. Based on the trial''s … Full story available on Benzinga.com